Whales with a lot of money to spend have taken a noticeably bullish stance on uniQure.
Looking at options history for uniQure (NASDAQ:QURE) we detected 53 trades.
If we consider the specifics of each trade, it is accurate to state that 60% of the investors opened trades with bullish expectations and 35% with bearish.
From the overall spotted trades, 16 are puts, for a total amount of $1,759,721 and 37, calls, for a total amount of $3,331,788.
Projected Price Targets
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $10.0 to $100.0 for uniQure over the recent three months.
Volume & Open Interest Trends
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for uniQure's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across uniQure's significant trades, within a strike price range of $10.0 to $100.0, over the past month.
uniQure Option Activity Analysis: Last 30 Days
Noteworthy Options Activity:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| QURE | CALL | SWEEP | BULLISH | 04/17/26 | $7.7 | $6.8 | $7.7 | $40.00 | $764.2K | 70 | 2.0K |
| QURE | PUT | TRADE | BULLISH | 01/16/26 | $34.7 | $32.5 | $32.5 | $60.00 | $650.0K | 307 | 200 |
| QURE | CALL | SWEEP | BEARISH | 04/17/26 | $6.4 | $3.8 | $5.9 | $45.00 | $365.8K | 34 | 945 |
| QURE | PUT | TRADE | BULLISH | 11/21/25 | $17.0 | $14.0 | $15.0 | $40.00 | $240.0K | 1.6K | 6 |
| QURE | CALL | TRADE | BULLISH | 01/16/26 | $19.8 | $16.8 | $19.0 | $10.00 | $190.0K | 819 | 216 |
About uniQure
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
After a thorough review of the options trading surrounding uniQure, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
Current Position of uniQure
- With a volume of 8,655,320, the price of QURE is down -58.77% at $27.91.
- RSI indicators hint that the underlying stock may be oversold.
- Next earnings are expected to be released in 11 days.
Expert Opinions on uniQure
In the last month, 1 experts released ratings on this stock with an average target price of $110.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. Click here for access. * An analyst from HC Wainwright & Co. persists with their Buy rating on uniQure, maintaining a target price of $110.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest uniQure options trades with real-time alerts from Benzinga Pro.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
